



SVB Securities Serves as Lead-Left Bookrunner for Belite Bio's (Nasdaq: BLTE) \$30 Million Follow-On Offering

Key Transaction Highlights

- Priced Tuesday, May 30th post-close
- Deal consisted of 2,000,000 ADSs, each representing one of the Company's ordinary shares, and warrants to purchase 2,000,000 ordinary shares represented by ADSs, at a public offering price of \$15.00 per ADS and accompanying warrant. The warrants will be exercisable immediately, will expire five years from the date of issuance and will have an exercise price of \$18.00 per ADS.
- Belite Bio intends to use the net proceeds of the offering for clinical trials and further clinical development of Tlnlarebant, funding its research and development of other pipeline products and for working capital and other general corporate purposes.
- This is SVB Securities' 1st bookrun offering for Belite Bio and 24th bookrun equity offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all SVB Securities distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
2151 Hawkins Street
Suite 1025
Charlotte, NC 28203

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111